JAK2 and pancreatic neoplasm: To further determine the JAK2/STAT3 signalling pathway roll in the cucurbitacin-mediated inhibition of pancreatic cancer growth, colivelin, an activator of the JAK2/STAT3 pathway, was used (50 μg/mL).